This year kicks off the second decade of Fierce Medtech’s annual Fierce 15 report. Not surprisingly, the startups featured on this year’s list are raising the bar for medtech developers everywhere. Staff writer Andrea Park and Editor-in-Chief Ayla Ellison discuss a few of the 15 startups that made the cut.  Plus, in this episode, we cover Illumina and Carl Icahn's proxy battle, Sanofi slashing insulin prices and more of this week's top headlines.  To learn more about the topics in this episode:  Fierce Medtech's 2022 Fierce 15 Illumina, Carl Icahn trade jabs amid looming proxy fight over $8B Grail buy Biogen, Novartis deliver one-two punch to Sangamo, walking away from deals in quick succession AbbVie's blockbuster-to-be Parkinson's combo hits a wall as FDA questions delivery pump Gilead's Yescarta puts pressure on BMS' Breyanzi with overall survival win in large B-cell lymphoma Selecta, Sobi rout gout in pair of phase 3 trials that could challenge Horizon Sanofi answers the call, joining Eli Lilly, Novo Nordisk in cutting insulin prices California invests $50M to partner with Civica Rx on insulin manufacturing The Top Line is produced by senior podcast producer Teresa Carey and managing editor Querida Anderson. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts. See omnystudio.com/listener for privacy information.